新薬apecotrepは 慢性腎臓病患者の尿中のタンパク質を 大幅に減少させました A new drug, apecotrep, greatly reduced protein in urine among chronic kidney disease patients in a Phase II trial.

Bohringer Ingerhemによると,実験薬のサルコトレプは,フェーズIIの臨床試験中に慢性腎疾患を持つ患者のたんぱく質を著しく減少させたという. Boehringer Ingelheim reports that its experimental drug apecotrep significantly reduced proteinuria in patients with chronic kidney disease during a Phase II clinical trial, marking a promising development in potential treatments for kidney-related conditions.